AICAR, MOTS-c, and the AMPK Pathway: A Research Overview
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) and MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) are two structurally distinct research compounds that share a common mechanistic interest: both have been observed in preclinical studies to interact with AMP-activated protein kinase (AMPK), a highly conserved cellular energy sensor with broad implications in metabolic biology. This convergence has made the AICAR MOTS-c AMPK pathway a focus of growing interest among researchers studying cellular bioenergetics, mitochondrial signalling, and metabolic regulation.
This article is intended for researchers and laboratory professionals exploring these compounds in a scientific context. For a broader overview of related research compounds, visit the Peptide Encyclopedia maintained by R&D Peptides.
Understanding the AMPK Pathway in Research Contexts
AMPK functions as a master regulator of cellular energy homeostasis. When intracellular AMP:ATP ratios rise — indicating low energy availability — AMPK becomes activated, initiating downstream processes associated with energy conservation and metabolic adaptation. In laboratory models, pharmacological activation of AMPK using synthetic compounds has been a valuable tool for interrogating these pathways without relying solely on dietary or physiological interventions.
AICAR acts as an AMPK activator by being phosphorylated intracellularly to ZMP, an AMP mimetic that directly stimulates AMPK. This mechanism has been studied extensively across cell lines and animal models, making AICAR one of the most widely referenced tool compounds in metabolic research. Foundational work by Merrill et al. (2002) demonstrated AICAR’s capacity to activate AMPK in skeletal muscle preparations, contributing significantly to the understanding of how AMPK influences glucose uptake and fatty acid oxidation at the cellular level.
MOTS-c: A Mitochondria-Derived Peptide with AMPK Interactions
MOTS-c is a peptide encoded within the mitochondrial genome — specifically the 12S ribosomal RNA gene — making it unique among mitochondria-derived peptides (MDPs). In preclinical studies, MOTS-c has been shown to translocate to the nucleus under metabolic stress conditions and regulate gene expression related to AMPK signalling. This positions MOTS-c as a retrograde mitochondrial signalling molecule with potential implications for understanding how organelles communicate metabolic status to the broader cell.
Research published by Lee et al. (2015) in Cell Metabolism identified MOTS-c as a regulator of insulin sensitivity and metabolic homeostasis in mouse models, operating through AMPK-dependent mechanisms. This study provided a pivotal basis for subsequent investigations into the compound’s role in mitochondrial-nuclear communication.
Researchers interested in this class of metabolic research compounds can explore the available catalogue at the Metabolic compounds section of the R&D Peptides shop.
Comparing AICAR and MOTS-c as Research Tools
While both compounds engage AMPK signalling, their mechanisms of action differ substantially, which is of direct relevance to experimental design:
- AICAR activates AMPK via direct intracellular mimicry of AMP, providing a well-characterised and reproducible activation signal.
- MOTS-c engages AMPK through upstream mitochondrial signalling, representing a more physiologically nuanced point of intervention.
- AICAR is a nucleoside analogue with a small-molecule profile, whereas MOTS-c is a 16-amino acid peptide requiring appropriate handling and storage protocols.
- The two compounds may offer complementary utility when studying different nodes of the AMPK regulatory network.
Further discussion of how AMPK intersects with longevity-related signalling pathways can also be found among the Longevity and Anti-Ageing compounds available for laboratory procurement.
Considerations for Laboratory Research
Studies using AICAR in rodent models have explored its effects on skeletal muscle metabolism, hepatic glucose production, and mitochondrial biogenesis. A notable contribution from Winder et al. (2000) documented AICAR-induced increases in mitochondrial enzyme activity in rat skeletal muscle, supporting the utility of this compound as a research probe in oxidative metabolism studies.
Researchers working with MOTS-c should note that its activity is context-dependent, with nuclear translocation appearing to be a key mediating step. Understanding the experimental conditions under which this occurs is important for interpreting results accurately.
Key Takeaways
- AICAR and MOTS-c are distinct research compounds that both engage the AMPK signalling pathway through different mechanisms.
- AICAR functions as an intracellular AMP mimetic; MOTS-c operates as a mitochondria-derived peptide influencing AMPK via upstream signalling.
- Preclinical studies suggest complementary utility for these compounds in metabolic research models.
- Both compounds require careful experimental design and appropriate laboratory conditions for meaningful data generation.
- Neither compound is approved for human use; all applications are strictly within research contexts.
Frequently Asked Questions
What is the relationship between AICAR and AMPK?
AICAR is phosphorylated intracellularly to form ZMP, which mimics AMP and directly activates AMPK. This makes it a commonly used pharmacological tool in studies investigating AMPK-dependent metabolic processes in cell and animal models.
How does MOTS-c differ from other mitochondria-derived peptides?
MOTS-c is encoded within the mitochondrial genome’s 12S rRNA region, distinguishing it from nuclear-encoded peptides. Its capacity to translocate to the nucleus and influence AMPK signalling represents a distinct retrograde communication mechanism not shared by all MDPs.
Can AICAR and MOTS-c be used together in research models?
Researchers have explored the use of multiple AMPK-targeting compounds in combination to dissect pathway interactions. Any such experimental design should be based on published protocols and conducted within approved laboratory frameworks.
Where can researchers source these compounds in the UK?
UK-based researchers can browse available metabolic research compounds through the R&D Peptides product catalogue, which includes a range of compounds relevant to AMPK pathway research.
All compounds are for laboratory research use only. Not for human consumption. This content is intended exclusively for qualified researchers and laboratory professionals operating within appropriate regulatory and ethical frameworks.
